20ca78ce-1972-4f55-81f2-22683da33c66
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59.3620807665982
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.470
- MITOTIC_SPINDLE+0.400
- E2F_TARGETS+0.380
- PROTEIN_SECRETION+0.380
- SPERMATOGENESIS+0.290
- ANDROGEN_RESPONSE+0.280
- UV_RESPONSE_DN+0.280
- INTERFERON_GAMMA_RESPONSE+0.260
- IL6_JAK_STAT3_SIGNALING+0.230
- INFLAMMATORY_RESPONSE+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.540
- OXIDATIVE_PHOSPHORYLATION-0.510
- DNA_REPAIR-0.370
- MYC_TARGETS_V1-0.290
- MYOGENESIS-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
- P53_PATHWAY-0.220
- XENOBIOTIC_METABOLISM-0.220
- ANGIOGENESIS-0.210
- ADIPOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016942 | — | — | 0.750 |
| 2 | 0c5e45df-149d-4667-8154-312c5e6f246b | — | — | 0.734 |
| 3 | TCGA-CR-7368-01A-11R-2132-07 | — | — | 0.728 |
| 4 | 8e357f45-e258-4685-91f6-1da2d0be4fc1 | — | — | 0.710 |
| 5 | 8828489a-e6fd-43ca-9232-e1b759d6edcf | — | — | 0.706 |
| 6 | TCGA-OR-A5JZ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.704 |
| 7 | b9389390-aa03-406c-957e-2bc264f9468e | — | — | 0.695 |
| 8 | TCGA-D8-A1J8-01A-11R-A13Q-07 | — | B | 0.694 |
| 9 | c22c07cb-8215-47e8-9525-074fda8d7d59 | — | — | 0.693 |
| 10 | MDT-AP-3270 | Med | Medulloblastoma | 0.692 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |